Navigation Links
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
Date:5/17/2013

ical needs for cancer and organ transplant patients. Through our global organization of talented and passionate employees, we are building a renewed and diversified portfolio, driven by the principles of innovation, personalization and patient access to medicines. We believe that delivering innovative treatment solutions requires collaboration with external experts, which is why we partner our own internal expertise with the best experts in scientific discovery and clinical research around the world.

About SanofiSanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and general
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... OAKS, Calif., July 29, 2014 Amgen (NASDAQ: ... the second quarter of 2014. Key results include: ... with 8 percent product sales growth driven by strong ... Kyprolis ® (carfilzomib), Prolia ® (denosumab) and ... 25 percent to $2.37, driven by higher revenues and ...
(Date:7/29/2014)... RIDGE, N.J. , July 29, 2014 ... biopharmaceutical company focused on the Phase 3 clinical development ... actively controllable antithrombotic drug system, today announced that it ... on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT ... corporate highlights. Interested participants and investors may ...
(Date:7/29/2014)... ST. PAUL, Minn. , July 29, 2014 /PRNewswire/ ... of medical devices using neuroblocking technology to treat obesity, ... it will host a conference call on Thursday, August ... financial results for the second quarter ended June 30, ... Conference Call Details The second quarter conference ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
...   Delcath Systems, Inc. (NASDAQ: DCTH ) ... Board. "As a widely respected hepatologist ... (ILCA), Dr. Gores will contribute a wealth of clinical ... our Medical Advisory Board," said Eamonn P. Hobbs, CEO ...
... PLEASANTON, Calif., Dec. 21, 2011  TriReme Medical, Inc. ... the treatment of complex vascular disease, announced today ... U.S. Food and Drug Administration to market its ... of occluded peripheral arteries. Chocolate was developed in ...
Cached Medicine Technology:Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 2Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 4TriReme Medical, Inc. Receives FDA 510(K) Clearance for Chocolate PTA Balloon Catheter 2
(Date:7/30/2014)... Frozen shoulder (Adhesive capsulitis) affects 10-20 percent of people ... condition which occurs most frequently in people between the ages ... and half years if not treated. , Adhesive capsulitis is ... it can render your shoulder so stiff, it's almost impossible ... in too much pain to get dressed in the first ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... time in a garden might help soothe the agitation that ... Looking at 17 past studies, British researchers found evidence that ... help soothe some dementia patients, anxiety. The study authors ... a tough subject to study -- and the evidence of ...
(Date:7/30/2014)... Young adults who were breastfed for three months ... risk of chronic inflammation associated with cardiovascular and ... School at Washington University in St. Louis. , ... have implications for children,s health decades later," said ... Brown School and a co-author of the study ...
(Date:7/30/2014)... 30, 2014 Everyone knows that the internet ... everyone. Whether people are looking for something to buy, trying ... dentist, the internet is pretty much always going to be ... in Lauderdale Florida is so happy to announce the launch ... presence into the modern age. Whether a person wants to ...
(Date:7/30/2014)... The North America aviation actuator market is ... America is expected to be the fastest growing region ... of 5.60%. , The commercial aircraft market offers ... assume prominence in the years to come. Commercial aviation ... has regained quickly, and the industry has been reliably ...
Breaking Medicine News(10 mins):Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 4
... , FRIDAY, Aug. 5 (HealthDay News) -- Believing in a ... ability to cope with uncertainty, researchers report. The paper, ... includes the results of two studies conducted by researchers at ... study of 332 Christians and Jews found that those who ...
... -- Smoking increases the risk of developing a heart rhythm ... researchers reviewed data from more than 15,000 people, aged 45 ... years, and found that there were 876 atrial fibrillation events ... rhythm was 1.32 times higher in former smokers and two ...
... FRIDAY, Aug. 5 (HealthDay News) -- For older Americans who ... that performance often trumps appearance. The boost in body ... exercise proved more satisfying than any change in appearance, especially ... advancing years, a shift in emphasis may occur, one that ...
... News) -- Children with HIV who receive antiretroviral treatments ... levels, and would benefit from guidelines aimed at reducing ... are published in JAIDS: Journal of Acquired Immune ... crucial step in minimizing cardiovascular disease complications and maximizing ...
... of Sexual Medicine reveals that in obese men ... sexual desire and lowers urinary tract symptoms. Researchers ... of the University of Adelaide studied 31 obese men ... received either a meal replacement-based low-calorie diet or a ...
... available in Spanish . , ANN ARBOR, Mich. ... can be used safely and effectively even in tumors from ... from the University of Michigan Comprehensive Cancer Center. Sentinel ... the first node where cancer would likely spread. If that ...
Cached Medicine News:Health News:Less Worry, Better Coping Seen Among Religious Folks 2Health News:With Age, Focus on Body Shifts From Appearance to Function 2Health News:With Age, Focus on Body Shifts From Appearance to Function 3Health News:Children's HIV Drugs May Cause High Cholesterol 2Health News:Sentinel node biopsy safe, effective in head and neck melanomas, U-M study finds 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: